SCHEMBL6029970

SCHEMBL6029970

COC(=O)C(=O)c1c[nH]c2c(Br)cccc12

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 4/20 0.51
BRPF1 P55201 1/20 0.44
DYRK1A Q13627 1/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
HPGD P15428 2/20 0.42
CREBBP Q92793 1/20 0.41
LMNA P02545 2/20 0.40
HTT P42858 2/20 0.40
ALOX5 P09917 1/20 0.39
MAP2K1 Q02750 1/20 0.38
CLEC4M Q9H2X3 1/20 0.38
MAPT P10636 1/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MEN1 O00255 1/20 0.37
AHR P35869 1/20 0.37
KMT2A Q03164 1/20 0.37
CNR2 P34972 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17113293 0.85 NR4A2 (0.70) NR4A2BRPF1DYRK1AALDH1A1KDM4E
SCHEMBL4232413 0.85 CLEC4M (0.50) NR4A2BRPF1ALDH1A1KDM4ELMNA
SCHEMBL989756 0.84 NR4A2 (0.73) NR4A2BRPF1ALDH1A1KDM4EHPGD
SCHEMBL6029339 0.82 ALDH1A1 (0.62) NR4A2BRPF1DYRK1AALDH1A1KDM4E
SCHEMBL14486971 0.82 NR4A2 (0.62) NR4A2BRPF1ALDH1A1KDM4EHPGD
SCHEMBL7210602 0.82 NR4A2 (0.51) NR4A2BRPF1
SCHEMBL26699761 0.82 NR4A2 (0.44) NR4A2BRPF1ALDH1A1KDM4EHPGD
SCHEMBL5269845 0.81 DYRK1A (0.46) NR4A2BRPF1DYRK1AALDH1A1KDM4E
SCHEMBL14631629 0.80 DYRK1A (0.45) NR4A2BRPF1DYRK1AALDH1A1KDM4E
SCHEMBL3762044 0.79 KDM4E (0.50) NR4A2BRPF1DYRK1AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109229-B2 Methods and compounds for treating proliferative diseases ELI LILLY AND COMPANY (US) 2006-09-19 US disclosed
EP-1325011-B1 METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES LILLY CO ELI (US) 2004-05-06 EP disclosed
US-20040048915-A1 Methods and compounds for treating proliferative diseases ENGLER THOMAS ALBERT (US) 2004-03-11 US disclosed
EP-1325011-A2 METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES ELI LILLY AND COMPANY (US) 2003-07-09 EP disclosed
WO-2002028861-A2 METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES ELI LILLY AND COMPANY (US) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048915-A1 Methods and compounds for treating proliferative diseases CDK4, CCNI, CCNA1 NR4A2 1135/4885BRPF1 1735/4885DYRK1A 2317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.